Evidence map›Paper›PMID 38362938›Full record

ArticleHippocampus2024

Distinct roles of Bdnf I and Bdnf IV transcript variant expression in hippocampal neurons.

Svitlana V Bach, Allison J Bauman, Darya Hosein, Jennifer J Tuscher, Lara Ianov, Kelsey M Greathouse, Benjamin W Henderson, Jeremy H Herskowitz, Keri Martinowich, Jeremy J Day

Open access · hybridAbstract read
In one paragraph

Article in Hippocampus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Svitlana V BachDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.ORCID 0000-0003-1134-9585
Allison J BaumanDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Darya HoseinDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Jennifer J TuscherDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Lara IanovDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.ORCID 0000-0002-1859-2118
Kelsey M GreathouseDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Benjamin W HendersonDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Jeremy H HerskowitzDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Keri MartinowichThe Lieber Institute for Brain Development, Baltimore, Maryland, USA.
Jeremy J DayDepartment of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
University of Alabama at Birmingham · USCivitan International · USJohns Hopkins University · US

Funding

Identifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9M
Regulation of neural activity in fear circuits by promoter IV derived BDNFR01MH105592 · NIMH · LIEBER INSTITUTE, INC. · PI MARTINOWICH, KERI · 2015 to 2024
$5.6M
UAB Research Training Program in Neurobiology of Cognition and Cognitive DisordersT32NS061788 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Farah Dominique Lubin · 2008 to 2026
$4.5M
Epigenetic Control of Brain Reward SystemsDP1DA039650 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DAY, JEREMY J · 2015 to 2019
$2.3M
Enhancer RNA Regulation of Experience-dependent Neuroepigenetic ProcessesR01MH114990 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DAY, JEREMY J · 2018 to 2022
$2.3M
Targeting Rho Kinases for Alzheimer's disease TherapeuticsR01AG054719 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HERSKOWITZ, JEREMY H. · 2017 to 2021
$1.9M
Synaptic Resilience to Tau in Alzheimer's DiseaseR21AG085379 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HERSKOWITZ, JEREMY H. · 2024 to 2025
$401k
CRISPR/dCas9-Targeted Manipulation of Bdnf Transcription in Synaptic Plasticity and Contextual LearningF32MH112304 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BACH, SVITLANA · 2016 to 2018
$174k
NIA NIH HHS R01 AG054719NIA NIH HHS R01 AG061800NIA NIH HHS R21 AG085379NIDA NIH HHS DP1 DA039650NIMH NIH HHS F32 MH112304NIMH NIH HHS R01 MH105592NIMH NIH HHS R01 MH114990NINDS NIH HHS T32 NS061788
6 · The paper itself

Abstract

Brain-derived neurotrophic factor (Bdnf) plays a critical role in brain development, dendritic growth, synaptic plasticity, as well as learning and memory. The rodent Bdnf gene contains nine 5' non-coding exons (I-IXa), which are spliced to a common 3' coding exon (IX). Transcription of individual Bdnf variants, which all encode the same BDNF protein, is initiated at unique promoters upstream of each non-coding exon, enabling precise spatiotemporal and activity-dependent regulation of Bdnf expression. Although prior evidence suggests that Bdnf transcripts containing exon I (Bdnf I) or exon IV (Bdnf IV) are uniquely regulated by neuronal activity, the functional significance of different Bdnf transcript variants remains unclear. To investigate functional roles of activity-dependent Bdnf I and IV transcripts, we used a CRISPR activation system in which catalytically dead Cas9 fused to a transcriptional activator (VPR) is targeted to individual Bdnf promoters with single guide RNAs, resulting in transcript-specific Bdnf upregulation. Bdnf I upregulation is associated with gene expression changes linked to dendritic growth, while Bdnf IV upregulation is associated with genes that regulate protein catabolism. Upregulation of Bdnf I, but not Bdnf IV, increased mushroom spine density, volume, length, and head diameter, and also produced more complex dendritic arbors in cultured rat hippocampal neurons. In contrast, upregulation of Bdnf IV, but not Bdnf I, in the rat hippocampus attenuated contextual fear expression. Our data suggest that while Bdnf I and IV are both activity-dependent, BDNF produced from these promoters may serve unique cellular, synaptic, and behavioral functions.

Indexed as

Brain-Derived Neurotrophic FactorHippocampusNeuronsAnimalsCells, CulturedExonsFearMaleRatsRats, Sprague-DawleyBdnf protein, ratBrain-Derived Neurotrophic Factorbrain‐derived neurotrophic factor (BDNF)contextual fear conditioningCRISPRasynaptic plasticitytranscription

Identifiers

PMID38362938
PMCPMC11039386
OpenAlexW4391879264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.